| Secondary |
| Product Used For Unknown Indication |
68.4% |
| Pulmonary Arterial Hypertension |
5.6% |
| Pulmonary Hypertension |
3.9% |
| Atrial Fibrillation |
2.2% |
| Gastrooesophageal Reflux Disease |
2.2% |
| Hypertension |
2.2% |
| Diabetes Mellitus |
1.7% |
| Pulmonary Embolism |
1.7% |
| Anticoagulant Therapy |
1.3% |
| Blood Cholesterol |
1.3% |
| Hepatitis C |
1.3% |
| Lung Carcinoma Cell Type Unspecified Stage 0 |
1.3% |
| Anaemia |
0.9% |
| Arthritis |
0.9% |
| Blood Cortisol |
0.9% |
| Blood Potassium Decreased |
0.9% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Coronary Artery Disease |
0.9% |
| Depression |
0.9% |
| Dizziness |
0.9% |
|
| International Normalised Ratio Increased |
18.2% |
| Transfusion |
9.1% |
| Pain In Extremity |
6.1% |
| Pneumonia |
6.1% |
| Respiratory Failure |
6.1% |
| Thrombocytopenia |
6.1% |
| Urticaria |
6.1% |
| Vomiting |
6.1% |
| Blood Disorder |
3.0% |
| Condition Aggravated |
3.0% |
| Fall |
3.0% |
| Haematoma |
3.0% |
| Haemoptysis |
3.0% |
| Haemorrhage |
3.0% |
| Insomnia |
3.0% |
| International Normalised Ratio Decreased |
3.0% |
| Lethargy |
3.0% |
| Memory Impairment |
3.0% |
| Movement Disorder |
3.0% |
| Nightmare |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
73.3% |
| Pulmonary Arterial Hypertension |
3.4% |
| Pulmonary Hypertension |
2.7% |
| Rheumatoid Arthritis |
2.5% |
| Pain |
2.1% |
| Atrial Fibrillation |
1.8% |
| Hypertension |
1.8% |
| Cellulitis |
1.5% |
| Prostate Cancer |
1.5% |
| Gout |
1.1% |
| Premedication |
1.0% |
| Osteoporosis Postmenopausal |
1.0% |
| Type 2 Diabetes Mellitus |
0.9% |
| Anticoagulant Therapy |
0.8% |
| Multiple Myeloma |
0.8% |
| Cardiac Failure Congestive |
0.8% |
| Deep Vein Thrombosis |
0.8% |
| Chronic Obstructive Pulmonary Disease |
0.7% |
| Osteoporosis |
0.7% |
| Prophylaxis |
0.7% |
|
| Death |
9.5% |
| Weight Decreased |
9.5% |
| Vomiting |
8.9% |
| Syncope |
8.2% |
| Pneumonia |
6.3% |
| Rash |
5.1% |
| Thrombosis |
5.1% |
| Toxicity To Various Agents |
5.1% |
| Drug Ineffective |
4.4% |
| Pulmonary Hypertension |
4.4% |
| Therapeutic Response Decreased |
4.4% |
| Atrial Fibrillation |
3.8% |
| Dyspnoea |
3.8% |
| Unevaluable Event |
3.8% |
| Cardiac Failure Congestive |
3.2% |
| Off Label Use |
3.2% |
| Urinary Tract Infection |
3.2% |
| Vision Blurred |
3.2% |
| Haemorrhage |
2.5% |
| Influenza |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
78.8% |
| Cough |
3.8% |
| Deep Vein Thrombosis |
1.9% |
| Hypotonia |
1.9% |
| Insomnia |
1.9% |
| Lung Carcinoma Cell Type Unspecified Stage 0 |
1.9% |
| Muscle Spasms |
1.9% |
| Pain |
1.9% |
| Prostate Cancer Metastatic |
1.9% |
| Pulmonary Embolism |
1.9% |
| Arthralgia |
1.0% |
| Prostate Cancer |
1.0% |
|
| International Normalised Ratio Increased |
25.0% |
| Rectal Haemorrhage |
25.0% |
| Urinary Tract Infection |
25.0% |
| Renal Failure |
12.5% |
| Skin Atrophy |
12.5% |
|
